Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration...

Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia

Doptelet (Avatrombopag): A 2nd Generation, Once Daily, Orally Administered TPO Receptor Agonist Approved for the Treatment of Thrombocytopenia - Global Drug Insight and Market Forecast 2017-2030 Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Doptelet (Avatrombopag) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Doptelet (avatrombopag)...